Lead Product(s) : ICP-248,Orelabrutinib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InnoCare Doses First Patient in Phase 3 trial of ICP-248 + Orelabrutinib for CLL/SLL
Details : ICP-248 is a novel, orally bioavailable, small molecule drug which is BCL2-selective inhibitor. It is currently being evaluated for the treatment of chronic lymphocytic leukemia.
Product Name : ICP-248
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2025
Lead Product(s) : ICP-248,Orelabrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesutoclax,Orelabrutinib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InnoCare Starts Phase III Trial of ICP-248 Plus Orelabrutinib for CLL/SLL
Details : ICP-248 is a B-cell lymphoma-2 (BCL2) inhibitor. It is being evaluated in combination with orelabrutinib for the treatment of chronic lymphocytic leukemia in China.
Product Name : ICP-248
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : Mesutoclax,Orelabrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesutoclax,Orelabrutinib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InnoCare Receives Approval for ICP-248 Clinical Trial with Orelabrutinib in China
Details : ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which is being evaluated in combination with orelabrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma.
Product Name : ICP-248
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : Mesutoclax,Orelabrutinib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orelabrutinib
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hibruka (orelabrutinib) is a highly selective BTK inhibitor developed for the treatment of cancers and autoimmune diseases. Currently under development for the treatment of primary immune thrombocytopenia (ITP) in China.
Product Name : Hibruka
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Orelabrutinib
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orelabrutinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hibruka (orelabrutinib) is a highly selective BTK inhibitor developed for the treatment of cancers and autoimmune diseases. Currently under development for for the treatment of MS, SLE, ITP and NMOSD in China.
Product Name : Hibruka
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 02, 2023
Lead Product(s) : Orelabrutinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orelabrutinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hibruka (orelabrutinib) is a highly selective BTK inhibitor developed for the treatment of cancers and autoimmune diseases. Currently under development for the treatment of R/R MZL in China.
Product Name : Hibruka
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2023
Lead Product(s) : Orelabrutinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orelabrutinib,Lenalidomide,Tafasitamab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. Tafasitamab is a humanized Fc-modified CD19 targeting immunotherapy.
Product Name : Hibruka
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : Orelabrutinib,Lenalidomide,Tafasitamab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orelabrutinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ICP-022 (orelabrutinib) is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases, was well tolerated with a safety profile in the patients with MZL.
Product Name : Hibruka
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2022
Lead Product(s) : Orelabrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orelabrutinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hibruka (orelabrutinib) is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. As a highly selective BTK inhibitor, orelabrutinib has demonstrated good efficacy and safety in the treatment of R/R M...
Product Name : Hibruka
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2022
Lead Product(s) : Orelabrutinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orelabrutinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : China International Capital
Deal Size : Undisclosed
Deal Type : Public Offering
Details : InnoCare will use the net proceeds from the STAR offering to fund its drug research and development of ICP-022 (orelabrutinib), drug R&D platform upgrade, marketing network upgrade, information technology upgrade and working capital projects.
Product Name : Hibruka
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 20, 2022
Lead Product(s) : Orelabrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : China International Capital
Deal Size : Undisclosed
Deal Type : Public Offering